

# DRAFT landscape of COVID-19 candidate vaccines – 9 September 2020

35 candidate vaccines in clinical evaluation

COVID-19 Vaccine developer/manufacturer	Vaccine platform	Type of candidate vaccine	Number of doses	Timing of doses	Route of Administration	Clinical Stage			
						Phase 1	Phase 1/2	Phase 2	Phase 3
University of Oxford/AstraZeneca	Non-Replicating Viral Vector	ChAdOx1-S	1		IM		<a href="https://www.pactr.org/record/PACTR202006922165132">PACTR202006922165132</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04516746">2020-001072-15</a> <a href="#">Interim Report</a>	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04516746">2020-001228-32</a>	<a href="https://www.clinicaltrials.gov/ct2/show/study/ISRCTN89951424">ISRCTN89951424</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04516746">NCT04516746</a>
CanSino Biological Inc./Beijing Institute of Biotechnology	Non-Replicating Viral Vector	Adenovirus Type 5 Vector	1		IM	<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000030906">ChiCTR2000030906</a> <a href="#">Study Report</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000031781">ChiCTR2000031781</a> <a href="#">Study Report</a>	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04526990">NCT04526990</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04540419">NCT04540419</a>
Gamaleya Research Institute	Non-Replicating Viral Vector	Adeno-based (rAd26-S+rAd5-S)	2	0,21 days	IM	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04436471">NCT04436471</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04437875">NCT04437875</a> <a href="#">Study Report</a>			<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04530396">NCT04530396</a>
Janssen Pharmaceutical Companies	Non-Replicating Viral Vector	Ad26COVS1	2	0, 56 days	IM		<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04436276">NCT04436276</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04505722">NCT04505722</a> (not yet recruiting)
Sinovac	Inactivated	Inactivated	2	0, 14 days	IM		<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04383574">NCT04383574</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04352608">NCT04352608</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04456595">NCT04456595</a> <a href="https://www.clinicaltrials.gov/ct2/show/study/669/UN6.KEP/EC/2020">669/UN6.KEP/EC/2020</a>
Wuhan Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000031809">ChiCTR2000031809</a> <a href="#">Interim Report</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000034780">ChiCTR2000034780</a>
Beijing Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000032459">ChiCTR2000032459</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/ChiCTR2000034780">ChiCTR2000034780</a>
Moderna/NIAID	RNA	LNP-encapsulated mRNA	2	0, 28 days	IM	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04283461">NCT04283461</a> <a href="#">Interim Report</a>		<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04405076">NCT04405076</a>	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT04470427">NCT04470427</a>

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

BioNTech/Fosun Pharma/Pfizer	RNA	3 LNP-mRNAs	2	0, 28 days	IM		<a href="#">2020-001038-36</a> <a href="#">ChiCTR2000034825</a> <a href="#">NCT04537949</a> <a href="#">Study Report</a>		<a href="#">NCT04368728</a>
Novavax	Protein Subunit	Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	2	0, 21 days	IM		<a href="#">NCT04368988</a> <a href="#">Study Report</a>	<a href="#">NCT04533399</a> (phase 2b)	
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences	Protein Subunit	Adjuvanted recombinant protein (RBD-Dimer)	2 or 3	0,28 or 0,28,56 days	IM	<a href="#">NCT04445194</a>		<a href="#">NCT04466085</a>	
Curevac	RNA	mRNA	2	0, 28 days	IM	<a href="#">NCT04449276</a>		<a href="#">NCT04515147</a>	
Institute of Medical Biology, Chinese Academy of Medical Sciences	Inactivated	Inactivated	2	0, 28 days	IM	<a href="#">NCT04412538</a>	<a href="#">NCT04470609</a>		
Research Institute for Biological Safety Problems, Rep of Kazakhstan	Inactivated	Inactivated	2	0, 21 days	IM		<a href="#">NCT04530357</a>		
Inovio Pharmaceuticals/ International Vaccine Institute	DNA	DNA plasmid vaccine with electroporation	2	0, 28 days	ID		<a href="#">NCT04447781</a> <a href="#">NCT04336410</a>		
Osaka University/ AnGes/ Takara Bio	DNA	DNA plasmid vaccine + Adjuvant	2	0, 14 days	IM		<a href="#">NCT04463472</a> <a href="#">NCT04527081</a>		
Cadila Healthcare Limited	DNA	DNA plasmid vaccine	3	0, 28, 56 days	ID		<a href="#">CTRI/2020/07/026352</a>		
Genexine Consortium	DNA	DNA Vaccine (GX-19)	2	0, 28 days	IM		<a href="#">NCT04445389</a>		
Bharat Biotech	Inactivated	Whole-Virion Inactivated	2	0, 14 days	IM		<a href="#">NCT04471519</a>		
Kentucky Bioprocessing, Inc	Protein Subunit	RBD-based	2	0, 21 days	IM		<a href="#">NCT04473690</a>		
Sanofi Pasteur/GSK	Protein Subunit	S protein (baculovirus production)	2	0, 21 days	IM		<a href="#">NCT04537208</a>		
Arcturus/Duke-NUS	RNA	mRNA			IM		<a href="#">NCT04480957</a>		
ReiThera/LEUKOCARE/Univercells	Non-Replicating Viral Vector	Replication defective Simian Adenovirus (GRAd) encoding S	1		IM	<a href="#">NCT04528641</a>			

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Clover Biopharmaceuticals Inc./GSK/Dynavax	Protein Subunit	Native like Trimeric subunit Spike Protein vaccine	2	0, 21 days	IM	<a href="#">NCT04405908</a>			
Vaxine Pty Ltd/Medytox	Protein Subunit	Recombinant spike protein with Advax™ adjuvant	1		IM	<a href="#">NCT04453852</a>			
University of Queensland/CSL/Seqirus	Protein Subunit	Molecular clamp stabilized Spike protein with MF59 adjuvant	2	0, 28 days	IM	<a href="#">ACTRN12620000674932p</a>			
Medigen Vaccine Biologics Corporation/NIAID/Dynavax	Protein Subunit	S-2P protein + CpG 1018	2	0, 28 days	IM	<a href="#">NCT04487210</a>			
Instituto Finlay de Vacunas, Cuba	Protein Subunit	RBD + Adjuvant	2	0, 28 days	IM	<a href="#">IFV/COR/04</a>			
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Protein Subunit	Peptide	2	0, 21 days	IM	<a href="#">NCT04527575</a>			
West China Hospital, Sichuan University	Protein Subunit	RBD (baculovirus production expressed in Sf9 cells)	2	0, 28 days	IM	<a href="#">ChiCTR2000037518</a>			
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme	Replicating Viral Vector	Measles-vector based	1 or 2	0, 28 days	IM	<a href="#">NCT04497298</a>			
Beijing Wantai Biological Pharmacy/Xiamen University	Replicating Viral Vector	Intranasal flu-based-RBD	1		IM	<a href="#">ChiCTR2000037782</a>			
Imperial College London	RNA	LNP-nCoVsaRNA	2		IM	<a href="#">ISRCTN17072692</a>			
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.	RNA	mRNA	2	0, 14 or 0, 28 days	IM	<a href="#">ChiCTR2000034112</a>			
Medicago Inc.	VLP	Plant-derived VLP adjuvanted with GSK or Dynavax adjs.	2	0, 21 days	IM	<a href="#">NCT04450004</a>			

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

145 candidate vaccines in preclinical evaluation

Platform	Type of candidate vaccine	Developer	Coronavirus target	Current stage of clinical evaluation/regulatory status- Coronavirus candidate	Same platform for non-Coronavirus candidates
DNA	DNA, engineered vaccine inserts compatible with multiple delivery systems	DIOSynVax Ltd / University of Cambridge	SARS-CoV-2 and Sarbeco-Coronaviruses	Pre-Clinical	
DNA	DNA vaccine	Ege University	SARS-CoV2	Pre-Clinical	
DNA	DNA plasmid vaccine RBD&N	Scancell/University of Nottingham/ Nottingham Trent University	SARS-CoV2	Pre-Clinical	
DNA	DNA plasmid vaccine S,S1,S2,RBD &N	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
DNA	DNA with electroporation	Karolinska Institute / Cobra Biologics (OPENCORONA Project)	SARS-CoV2	Pre-Clinical	
DNA	DNA with electroporation	Chula Vaccine Research Center	SARS-CoV2	Pre-Clinical	
DNA	DNA	Takis/Applied DNA Sciences/Evvivax	SARS-CoV2	Pre-Clinical	
DNA	Plasmid DNA, Needle-Free Delivery	Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet	SARS-CoV2	Pre-Clinical	SARS
DNA	DNA vaccine	BioNet Asia	SARS-CoV2	Pre-Clinical	
DNA	msDNA vaccine	Mediphage Bioceuticals/University of Waterloo	SARS-CoV2	Pre-Clinical	
DNA	DNA vaccine	Entos Pharmaceuticals	SARS-CoV2	Pre-Clinical	
DNA	bacTRL-Spike	Symvivo	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + alum	KM Biologics	SARS-CoV2	Pre-Clinical	JE, Zika
Inactivated	Inactivated	Selcuk University	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated	Erciyas University	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated whole virus	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated	Beijing Minhai Biotechnology Co., Ltd.	SARS-CoV2	Pre-Clinical	
Inactivated	TBD	Osaka University/ BIKEN/ NIBIOHN	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + CpG 1018	Sinovac/Dynavax	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + CpG 1018	Valneva/Dynavax	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated		SARS-CoV2	Pre-Clinical	
Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Mehmet Ali Aydinlar University / Acibadem Labmed Health Services A.S.	SARS-CoV2	Pre-Clinical	

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Codagenix/Serum Institute of India	SARS-CoV2	Pre-Clinical	HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Indian Immunologicals Ltd/Griffith University	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Sendai virus vector	ID Pharma	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Adenovirus-based	Ankara University	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Adeno-associated virus vector (AAVCOVID)	Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	MVA encoded VLP	GeoVax/BravoVax	SARS-CoV2	Pre-Clinical	LASV, EBOV, MARV, HIV
Non-replicating viral vector	MVA-S encoded	DZIF – German Center for Infection Research/IDT Biologika GmbH	SARS-CoV2	Pre-clinical	Many
Non-replicating viral vector	MVA-S	IDIBAPS-Hospital Clinic, Spain	SARS-CoV2	Pre-clinical	
Non-Replicating Viral Vector	adenovirus-based NasoVAX expressing SARS2-CoV spike protein	Altimune	SARS-CoV2	Pre-Clinical	influenza
Non-Replicating Viral Vector	Adeno5-based	Erciyes University	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	2nd Gen E2b- Ad5 Spike, RBD, Nucleocapsid Subcutaneous&Oral	ImmunityBio, Inc. & NantKwest, Inc.	SARS-CoV2	Pre-Clinical	flu, Chik, Zika, EBOV, LASV, HIV/SIV,Cancer
Non-Replicating Viral Vector	Ad5 S (GREVAX™ platform)	Greffex	SARS-CoV2	Pre-Clinical	MERS
Non-Replicating Viral Vector	Oral Ad5 S	Stabilitech Biopharma Ltd	SARS-CoV2	Pre-Clinical	Zika, VZV, HSV-2 and Norovirus
Non-Replicating Viral Vector	adenovirus-based + HLA-matched peptides	Valo Therapeutics Ltd	Pan-Corona	Pre-Clinical	
Non-Replicating Viral Vector	Oral Vaccine platform	Vaxart	SARS-CoV2	Pre-Clinical	InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE
Non-Replicating Viral Vector	MVA expressing structural proteins	Centro Nacional Biotecnología (CNB-CSIC), Spain	SARS-CoV2	Pre-Clinical	Multiple candidates
Non-Replicating Viral Vector	parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein	University of Georgia/University of Iowa	SARS-CoV2	Pre-Clinical	MERS
Non-Replicating Viral Vector	Recombinant deactivated rabies virus containing S1	Bharat Biotech/Thomas Jefferson University	SARS-CoV2	Pre-Clinical	HeV, NiV, EBOV, LASSA, CCHFV, MERS
Non-Replicating Viral Vector	Influenza A H1N1 vector	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant	National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO, Thailand	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptides	Neo7Logic	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant spike protein with Essai O/W 1849101 adjuvant	Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant S protein	Max-Planck-Institute of Colloids and Interfaces	SARS-CoV2	Pre-Clinical	

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Protein Subunit	RBD protein (baculovirus production) + FAR-Squalene adjuvant	Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit	Research Institute for Biological Safety Problems, Rep of Kazakhstan	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD-protein	Mynvax	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant S protein	Izmir Biomedicine and Genome Center	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide + novel adjuvant	Bogazici University	SARS-CoV2	Pre-Clinical	
Protein Subunit	S subunit intranasal liposomal formulation with GLA/3M052 adjs.	University of Virginia	SARS-CoV2	Pre-Clinical	
Protein Subunit	S-Protein (Subunit) + Adjuvant, E coli based Expression	Helix Biogen Consult, Ogbomoso & Trinity Immono-efficient Laboratory, Ogbomoso, Oyo State, Nigeria.	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit S,N,M&S1 protein	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit	University of San Martin and CONICET, Argentina	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD protein fused with Fc of IgG + Adj.	Chulalongkorn University/GPO, Thailand	SARS-CoV2	Pre-Clinical	
Protein Subunit	Capsid-like Particle	AdaptVac (PREVENT-nCoV consortium)	SARS-CoV2	Pre-Clinical	
Protein Subunit	Drosophila S2 insect cell expression system VLPs	ExpreS2ion	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide antigens formulated in LNP	IMV Inc	SARS-CoV2	Pre-Clinical	
Protein Subunit	S protein	WRAIR/USAMRIID	SARS-CoV2	Pre-Clinical	
Protein Subunit	S protein +Adjuvant	National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma	SARS-CoV2	Pre-Clinical	Influenza
Protein Subunit	VLP-recombinant protein + Adjuvant	Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan	SARS-CoV2	Pre-Clinical	
Protein Subunit	microneedle arrays S1 subunit	Univ. of Pittsburgh	SARS-CoV2	Pre-Clinical	MERS
Protein Subunit	Peptide	Vaxil Bio	SARS-CoV2	Pre-Clinical	
Protein Subunit	Adjuvanted protein subunit (RBD)	Biological E Ltd	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide	Flow Pharma Inc	SARS-CoV2	Pre-Clinical	Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine
Protein Subunit	S protein	AJ Vaccines	SARS-CoV2	Pre-Clinical	
Protein Subunit	Ii-Key peptide	Generex/EpiVax	SARS-CoV2	Pre-Clinical	Influenza, HIV, SARS-CoV
Protein Subunit	S protein	EpiVax/Univ. of Georgia	SARS-CoV2	Pre-Clinical	H7N9
Protein Subunit	Protein Subunit EPV-CoV-19	EpiVax	SARS-CoV2	Pre-Clinical	
Protein Subunit	gp-96 backbone	Heat Biologics/Univ. Of Miami	SARS-CoV2	Pre-Clinical	NSCLC, HIV, malaria, Zika

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Protein Subunit	Subunit vaccine	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Protein Subunit	S1 or RBD protein	Baylor College of Medicine	SARS-CoV2	Pre-Clinical	SARS
Protein Subunit	Subunit protein, plant produced	iBio/CC-Pharming	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant protein, nanoparticles (based on S-protein and other epitopes)	Saint-Petersburg scientific research institute of vaccines and serums	SARS-CoV2	Pre-Clinical	
Protein Subunit	COVID-19 XWG-03 truncated S (spike) proteins	Innovax/Xiamen Univ./GSK	SARS-CoV2	Pre-Clinical	HPV
Protein Subunit	Adjuvanted microsphere peptide	VIDO-InterVac, University of Saskatchewan	SARS-CoV2	Pre-Clinical	
Protein Subunit	Synthetic Long Peptide Vaccine candidate for S and M proteins	OncoGen	SARS-CoV2	Pre-Clinical	
Protein Subunit	Oral E. coli-based protein expression system of S and N proteins	MIGAL Galilee Research Institute	SARS-CoV2	Pre-Clinical	
Protein Subunit	Nanoparticle vaccine	LakePharma, Inc.	SARS-CoV2	Pre-Clinical	
Protein Subunit	Plant-based subunit (RBD-Fc + Adjuvant)	Baiya Phytopharm/ Chula Vaccine Research Center	SARS-CoV2	Pre-Clinical	
Protein Subunit	OMV-based vaccine	Quadram Institute Biosciences	SARS-CoV2	Pre-Clinical	Flu A, plague
Protein Subunit	OMV-based vaccine	BiOMViS Srl/Univ. of Trento	SARS-CoV2	Pre-Clinical	
Protein subunit	structurally modified spherical particles of the tobacco mosaic virus (TMV)	Lomonosov Moscow State University	SARS-CoV2	Pre-Clinical	rubella, rotavirus
Protein Subunit	Spike-based	University of Alberta	SARS-CoV2	Pre-Clinical	Hepatitis C
Protein Subunit	Recombinant S1-Fc fusion protein	AnyGo Technology	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant protein	Yisheng Biopharma	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant S protein in IC-BEVS	Vabiotech	SARS-CoV2	Pre-Clinical	
Protein Subunit	Orally delivered, heat stable subunit	Applied Biotechnology Institute, Inc.	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptides derived from Spike protein	Axon Neuroscience SE	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit	MOGAM Institute for Biomedical Research, GC Pharma	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD-based	Neovii/Tel Aviv University	SARS-CoV2	Pre-Clinical	
Protein Subunit	Outer Membrane Vesicle (OMV)-subunit	Intravacc/Epivax	SARS-CoV2	Pre-Clinical	
Protein Subunit	Outer Membrane Vesicle(OMV)-peptide	Intravacc/Epivax	SARS-CoV2	Pre-Clinical	
Protein Subunit	Spike-based (epitope screening)	ImmunoPrecise/LiteVax BV	SARS-CoV2	Pre-Clinical	
Replicating Bacteria Vector	Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD	Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	YF17D Vector	KU Leuven	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Vector	Cadila Healthcare Limited	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Virus (S, N targets)	DZIF – German Center for Infection Research/CanVirex AG	SARS-CoV2	Pre-clinical	Zika, H7N9, CHIKV

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Replicating Viral Vector	Horsepox vector expressing S protein	Tonix Pharma/Southern Research	SARS-CoV2	Pre-Clinical	Smallpox, monkeypox
Replicating Viral Vector	Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)	BiOCAD and IEM	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Attenuated Influenza expressing an antigenic portion of the Spike protein	Fundação Oswaldo Cruz and Instituto Buntantan	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Influenza vector expressing RBD	University of Hong Kong	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein.	IAVI/Merck	SARS-CoV2	Pre-Clinical	Ebola, Marburg, Lassa
Replicating Viral Vector	Replicating VSV vector-based DC-targeting	University of Manitoba	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	VSV-S	University of Western Ontario	SARS-CoV2	Pre-Clinical	HIV, MERS
Replicating Viral Vector	VSV-S	Aurobindo	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	VSV vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	VSV-S	Israel Institute for Biological Research/Weizmann Institute of Science	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	M2-deficient single replication (M2SR) influenza vector	UW–Madison/FluGen/Bharat Biotech	SARS-CoV2	Pre-Clinical	influenza
Replicating Viral Vector	Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)	Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Avian paramyxovirus vector (APMV)	The Lancaster University, UK	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA encoding S	Max-Planck-Institute of Colloids and Interfaces	SARS-CoV2	Pre-Clinical	
RNA	Self-amplifying RNA	Genova	SARS-CoV2	Pre-Clinical	
RNA	mRNA	Selcuk University	SARS-CoV2	Pre-Clinical	
RNA	LNP-mRNA	Translate Bio/Sanofi Pasteur	SARS-CoV2	Pre-Clinical	
RNA	LNP-mRNA	CanSino Biologics/Precision NanoSystems	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA cocktail encoding VLP	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA encoding RBD	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma	SARS-CoV2	Pre-Clinical	

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.



RNA	Replicating Defective SARS-CoV-2 derived RNAs	Centro Nacional Biotecnología (CNB-CSIC), Spain	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA	University of Tokyo/ Daiichi-Sankyo	SARS-CoV2	Pre-Clinical	MERS
RNA	Liposome-encapsulated mRNA	BIOCAD	SARS-CoV2	Pre-Clinical	
RNA	Several mRNA candidates	RNAimmune, Inc.	SARS-CoV2	Pre-Clinical	
RNA	mRNA	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
RNA	mRNA	China CDC/Tongji University/Stermina	SARS-CoV2	Pre-Clinical	
RNA	LNP-mRNA	Chula Vaccine Research Center/University of Pennsylvania	SARS-CoV2	Pre-Clinical	
RNA	mRNA in an intranasal delivery system	eTheRNA	SARS-CoV2	Pre-Clinical	
RNA	mRNA	Greenlight Biosciences	SARS-CoV2	Pre-Clinical	
RNA	mRNA	IDIBAPS-Hospital Clinic, Spain	SARS-CoV2	Pre-Clinical	
T-cell based	CD8 T cell peptide targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins	OSE immunotherapeutics	SARS-CoV2	Pre-Clinical	
VLP	Virus-like particle-based Dendritic Cell(DC)-targeting vaccine	University of Manitoba	SARS-CoV2	Pre-Clinical	
VLP	VLP	Bezmialem Vakif University	SARS-CoV2	Pre-Clinical	
VLP	VLP	Middle East Technical University	SARS-CoV2	Pre-Clinical	
VLP	Enveloped Virus-Like Particle (eVLP)	VBI Vaccines Inc.	SARS-CoV-2, SARS-CoV, & MERS-CoV	Pre-Clinical	CMV, GBM, Zika
VLP	S protein integrated in HIV VLPs	IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols	SARS-CoV2	Pre-Clinical	
VLP	VLP + Adjuvant	Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital	SARS-CoV2	Pre-Clinical	
VLP	Virus-like particles, lentivirus and baculovirus vehicles	Navarrabiomed, Oncoimmunology group	SARS-CoV2	Pre-Clinical	
VLP	Virus-like particle, based on RBD displayed on virus-like particles	Saiba GmbH	SARS-CoV2	Pre-Clinical	
VLP	ADDomer™ multiepitope display	Imophoron Ltd and Bristol University's Max Planck Centre	SARS-CoV2	Pre-Clinical	
VLP	Unknown	Doherty Institute	SARS-CoV2	Pre-Clinical	

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

VLP	VLP	OSIVAX	SARS-CoV1 SARS-CoV2	Pre-Clinical	
VLP	eVLP	ARTES Biotechnology	SARS-CoV2	Pre-Clinical	malaria
VLP	VLPs peptides/whole virus	Univ. of Sao Paulo	SARS-CoV2	Pre-Clinical	

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.